Back to Search
Start Over
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
- Source :
-
Melanoma research [Melanoma Res] 2006 Feb; Vol. 16 (1), pp. 65-9. - Publication Year :
- 2006
-
Abstract
- Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases. Twenty-three patients with advanced inoperable melanoma were hospitalized for 5-6 days for the following treatment: cisplatin 20 mg/m daily for 4 days, vinblastine 1.6 mg/m daily for 4 days and oral temozolomide 250 mg/m daily for 5 days, with 18 x 10 IU/m intravenous interleukin-2 by continuous infusion for 4 days (the dose was cut daily by 50%) and 5 x 10 U/m interferon-alfa subcutaneously daily for 5 days, repeated at 28-day intervals for a maximum of nine courses. According to the standard World Health Organization response criterion, the objective response rate was 43.4% and the median survival was 18.6 months. All but one patient survived for more than 12 months, and no responding patient progressed first in the brain. Substituting dacarbazine by temozolomide in the MD Anderson melanoma section protocol appears to offer protection against dissemination of brain metastases, equal activity in the periphery and a possible lower incidence of toxicity due to the oral route.
- Subjects :
- Adult
Aged
Cisplatin administration & dosage
Dacarbazine administration & dosage
Dacarbazine analogs & derivatives
Disease-Free Survival
Female
Humans
Infusions, Intravenous
Interferon alpha-2
Interferon-alpha administration & dosage
Interleukin-2 administration & dosage
Male
Melanoma pathology
Middle Aged
Recombinant Proteins
Skin Neoplasms drug therapy
Skin Neoplasms pathology
Survival Rate
Temozolomide
Treatment Outcome
Vinblastine administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Brain Neoplasms drug therapy
Brain Neoplasms secondary
Melanoma drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0960-8931
- Volume :
- 16
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Melanoma research
- Publication Type :
- Academic Journal
- Accession number :
- 16432458
- Full Text :
- https://doi.org/10.1097/01.cmr.0000183921.46031.93